Literature DB >> 28062613

Consensus or Controversy?: Evolution of Criteria for Myocardial Infarction After Percutaneous Coronary Intervention.

Pierluigi Tricoci1.   

Abstract

BACKGROUND: The definition and the clinical implications of myocardial infarction (MI) occurring in the setting of percutaneous coronary intervention have been subjects of unresolved controversy. As a result of the use of more sensitive diagnostic tools such as cardiac troponin, the expanding evidence, and the ensuing debate, the definition of procedural MI (pMI) has evolved, leading to several revisions, different proposed definitions, and lack of standardization in randomized clinical trials. CONTENT: In this review, we will describe the key clinical data on cardiac biomarkers, creatine kinase isoenzyme MB and cTn, in the setting of percutaneous coronary intervention and the main issues that have lead to various consensus documents with a proposed definition of pMI. We will focus on the rationale of the current "Third Universal Definition of Myocardial Infarction" and of the alternative approach proposed by the Society for Cardiovascular Angiography and Interventions.
SUMMARY: The definition of pMI is an evolving field where the Third Universal MI definition represents the best attempt to date to incorporate available evidence along with scientific and clinical judgment into criteria to ensure adequate specificity in the diagnosis and the relevant prognostic significance, while trying to maintain sensitivity. Questions on the recommended criteria and their practical implementation remain, but the Third Universal definition document represents an important milestone toward a better standardization and enhanced consensus on the pMI definition.
© 2016 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28062613     DOI: 10.1373/clinchem.2016.255208

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54.

Authors:  Marc P Bonaca; Stephen D Wiviott; David A Morrow; P Gabriel Steg; Christian Hamm; Deepak L Bhatt; Robert F Storey; Marc Cohen; Julia Kuder; KyungAh Im; Giulia Magnani; Andrzej Budaj; José C Nicolau; Alexander Parkhomenko; José López-Sendón; Mikael Dellborg; Rafael Diaz; Frans Van de Werf; Ramón Corbalán; Assen Goudev; Eva C Jensen; Per Johanson; Eugene Braunwald; Marc S Sabatine
Journal:  J Am Heart Assoc       Date:  2018-11-20       Impact factor: 5.501

2.  Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention.

Authors:  Zhuoshan Huang; Xing Shui; Yesheng Ling; Linli Zhou; Wenqi Shi; Yanting Luo; Suhua Li; Jieming Zhu; Shujie Yu; Jinlai Liu
Journal:  Clin Cardiol       Date:  2020-12-02       Impact factor: 2.882

3.  Myocardial damage associated with elective percutaneous coronary intervention in Chinese patients: a retrospective study.

Authors:  Shengjia Sun; Yang Ou; Haiming Shi; Jianfeng Luo; Xinping Luo; Yunzhi Shen; Yufei Chen; Xiaojin Liu; Zhidong Zhu; Wei Shen
Journal:  J Int Med Res       Date:  2020-03       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.